A Phase 1b, Open Label Study of the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of 100 mg Clemizole Hydrochloride Administered Orally Twice a Day for 28 Days Immediately Prior to Initiation of Treatment With HCV Standard of Care Therapy in Treatment-Naive Subjects Chronically Infected With HCV.
Phase of Trial: Phase I
Latest Information Update: 25 Feb 2011
At a glance
- Drugs Clemizole (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics
- Acronyms CLEAN-1
- 25 Feb 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 25 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Aug 2009 According to an Eiger BioPharmaceuticals media release, the first patients have been dosed.